The effectiveness of oxytocin for treating substance use disorders: A systematic review of randomized placebo-controlled trials

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 5,81 MB, PDF-dokument

  • Angelina Isabella Mellentin
  • Sara Wallhed Finn
  • Lotte Skøt
  • Daniel Thaysen-Petersen
  • Nicolaj Mistarz
  • Fink-Jensen, Anders
  • Dorthe Grüner Nielsen

Oxytocin is gaining traction in the treatment of various substance use disorders (SUD). We performed a systematic review assessing the efficacy of oxytocin for treating different SUD. The electronic databases MEDLINE, EMBASE, CENTRAL, and the Cochrane Database of Systematic Reviews were searched for randomized controlled trials examining the effects of oxytocin vs. placebo in SUD samples. Quality assessment was conducted using a Cochrane validated checklist. A total of 17 trials with unique samples were identified. These were conducted on participants with SUD involving alcohol (n = 5), opioids (n = 3), opioids and/or cocaine/other stimulants (n = 3), cannabis (n = 2), or nicotine (n = 4). Across the SUD-groups, oxytocin reduced withdrawal symptoms (3/5 trials), negative emotional states (4/11 trials), cravings (4/11 trials), cue-induced cravings (4/7 trials), and consumption (4/8 trials). Sixteen trials had an overall considerable risk of bias. In conclusion, although oxytocin showed some promising therapeutic effects, the findings are too inconsistent and the trials too heterogeneous to derive any firm conclusions. Sounder methodological and well-powered trials are warranted.

TidsskriftNeuroscience and Biobehavioral Reviews
Antal sider16
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
We would like to thank Linda Bassi and Helena Bassi for their assistance with screening the literature as part of their master's thesis.

Publisher Copyright:
© 2023 The Authors

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 367256637